Xenikos Revenue and Competitors
Estimated Revenue & Valuation
- Xenikos's estimated annual revenue is currently $310k per year.
- Xenikos's estimated revenue per employee is $155,000
Employee Data
- Xenikos has 2 Employees.
- Xenikos grew their employee count by -88% last year.
Xenikos's People
| Name | Title | Email/Phone |
|---|---|---|
1 | COO | Reveal Email/Phone |
2 | Manager CMC RA | Reveal Email/Phone |
Xenikos Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Xenikos?
Xenikos, a private, clinical-stage biopharmaceutical company, is focused on developing innovative immunotherapies, based on conjugated antibodies, designed to quickly and safely reset the immune system in patients with a severe immune disease or post-transplantation rejection. Xenikos' flagship product, T-Guard®, is being prepared to enter Phase 3 testing for the treatment of acute graft-versus-host-disease.
keywords:N/A
N/A
Total Funding
2
Number of Employees
$310k
Revenue (est)
-88%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Nijmegen
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.2M | 2 | -60% | N/A |
#2 | $0.2M | 2 | -67% | N/A |
#3 | $0.8M | 4 | 0% | N/A |
#4 | $0.6M | 8 | -33% | N/A |
#5 | $0.7M | 9 | -53% | N/A |